JBT-101

Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) announced Monday top line results from a second stage trial of its Resunab (JBT-101) therapy for the treatment of systemic sclerosis treatment. Liisa Bayko of JMP Securities commented in a report that there appears to be some confusion...